Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:ACRS

Aclaris Therapeutics - ACRS Stock Forecast, Price & News

$17.53
-0.17 (-0.96%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$17.44
$17.85
50-Day Range
$13.07
$18.37
52-Week Range
$9.26
$18.96
Volume
65,500 shs
Average Volume
412,158 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Aclaris Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
105.4% Upside
$36.00 Price Target
Short Interest
Bearish
7.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of Aclaris Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.64 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.41) to ($1.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

763rd out of 1,044 stocks

Pharmaceutical Preparations Industry

363rd out of 510 stocks

ACRS stock logo

About Aclaris Therapeutics (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

Aclaris Therapeutics Announces Key Leadership Transitions
Aclaris Therapeutics Looks Promising on the Charts
Aclaris Therapeutics Tops Q1 EPS by 9c
Aclaris Therapeutics Q1 2022 Earnings Preview
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Company Calendar

Last Earnings
11/02/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+105.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-90,860,000.00
Net Margins
-349.26%
Pretax Margin
-349.26%

Debt

Sales & Book Value

Annual Sales
$6.76 million
Book Value
$3.30 per share

Miscellaneous

Free Float
62,215,000
Market Cap
$1.17 billion
Optionable
Optionable
Beta
0.55

Key Executives

  • Dr. Neal S. Walker D.O. (Age 52)
    Co-Founder, CEO & Director
    Comp: $965.59k
  • Mr. Frank  RuffoMr. Frank Ruffo (Age 56)
    Co-Founder, CFO , Sec. & Treasurer
    Comp: $590.85k
  • Dr. Joseph  MonahanDr. Joseph Monahan
    Chief Scientific Officer
  • Dr. Douglas J. Manion Frcp(C) (Age 61)
    M.D., Pres & COO
  • Mr. Robert A. Doody Jr.
    VP of Investor Relations
  • Mr. Matthew Rothman J.D.
    VP of Legal & Compliance
  • Dr. Jon Jacobsen Ph.D.
    Sr. VP of Chemistry
  • Dr. Paul S. Changelian Ph.D.
    Sr. VP of Biology
  • Mr. James Loerop (Age 57)
    Chief Bus. Officer
  • Dr. Ian Anderson Ph.D.
    Exec. VP of Translational R&D













ACRS Stock - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price forecast for 2023?

5 analysts have issued 1 year price targets for Aclaris Therapeutics' stock. Their ACRS share price forecasts range from $26.00 to $50.00. On average, they anticipate the company's share price to reach $36.00 in the next year. This suggests a possible upside of 105.4% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How have ACRS shares performed in 2022?

Aclaris Therapeutics' stock was trading at $14.54 at the start of the year. Since then, ACRS stock has increased by 20.6% and is now trading at $17.53.
View the best growth stocks for 2022 here
.

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.07. The biotechnology company earned $1.66 million during the quarter, compared to analysts' expectations of $1.82 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 39.41% and a negative net margin of 349.26%.

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?
What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.21%), Vanguard Group Inc. (4.40%), Point72 Asset Management L.P. (2.78%), Laurion Capital Management LP (1.96%), State Street Corp (1.95%) and Renaissance Technologies LLC (1.78%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $17.53.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $1.17 billion and generates $6.76 million in revenue each year. The biotechnology company earns $-90,860,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.

This page (NASDAQ:ACRS) was last updated on 11/28/2022 by MarketBeat.com Staff